PureTech Health plc (PRTC)

Market Cap	465.36M
Revenue (ttm)	468,000
Net Income (ttm)	-82.47M
Shares Out	239.42M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	463
Open	20.01
Previous Close	20.20
Day's Range	20.01 - 20.01
52-Week Range	19.02 - 34.00
Beta	0.99
Analysts	Buy
Price Target	45.00 (+124.89%)
Earnings Date	Aug 28, 2024

About PRTC

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 90
• Stock Exchange: NASDAQ
• Ticker Symbol: PRTC
• Website: https://www.puretechhealth.com

Financial Performance

In 2023, PureTech Health's revenue was $3.33 million, a decrease of -78.68% compared to the previous year's $15.62 million. Losses were -$65.70 million, 30.5% more than in 2022.

Analyst Forecast

According to one analyst, the rating for PRTC stock is "Buy" and the 12-month stock price forecast is $45.0.

Price Target

$45.0

(124.89% upside)

Analyst Consensus: Buy